scholarly journals Oral administration of valganciclovir reduces clinical signs, virus shedding and cell‐associated viraemia in ponies experimentally infected with equid herpesvirus‐1

2021 ◽  
Vol 53 (S56) ◽  
pp. 56-56
Keyword(s):  
Oral Administration ◽  
Clinical Signs ◽  
Virus Shedding ◽  
Equid Herpesvirus ◽  
Herpesvirus 1

scholarly journals Safety and immunogenicity of a glycoprotein E gene-deleted bovine herpesvirus 1 strain as a candidate vaccine strain

2016 ◽  
Vol 36 (11) ◽  
pp. 1067-1074
Author(s):  
Marcelo Weiss ◽  
◽  
Deniz Anziliero ◽  
Mathias Martins ◽  
Rudi Weiblen ◽  
...  
Keyword(s):  
Acute Infection ◽  
Clinical Signs ◽  
Bovine Herpesvirus ◽  
Elisa Test ◽  
Bovine Herpesvirus 1 ◽  
Glycoprotein E ◽  
Virus Shedding ◽  
Group I ◽  
Virus Dose ◽  
Herpesvirus 1

ABSTRACT: A glycoprotein E-deleted Brazilian bovine herpesvirus 1 (BoHV-1gEΔ) was tested regarding to safety and immunogenicity. Intramuscular inoculation of young calves with a high virus dose did not result in clinical signs or virus shedding during acute infection or after dexamethasone administration. Calves vaccinated once IM (group I) or subcutaneously (group II) with live BoHV-1gEΔ or twice with inactivated virus plus aluminum hydroxide (group IV) or Montanide™ (group V) developed VN titers of 2 to 8 (GMT:2); 2 to 4 (GMT:1.65); 2 to 16 (GMT:2.45) and 2 to 128 (GMT:3.9), respectively. All BoHV-1gEΔ vaccinated calves remained negative in an anti-gE ELISA. Lastly, six young calves vaccinated with live BoHV-1gEΔ and subsequently challenged with a virulent BoHV-1 strain shed less virus and developed only mild and transient nasal signs comparing to unvaccinated calves. Thus, the recombinant BoHV-1gEΔ is safe and immunogenic for calves and allows for serological differentiation by a gE-ELISA test.

scholarly journals Intranasal IgG4/7 antibody responses protect horses against equid herpesvirus-1 (EHV-1) infection including nasal virus shedding and cell-associated viremia

Virology ◽  
2019 ◽  
Vol 531 ◽  
pp. 219-232 ◽  
Author(s):  
Gillian Perkins ◽  
Susanna Babasyan ◽  
Alison E. Stout ◽  
Heather Freer ◽  
Alicia Rollins ◽  
...  
Keyword(s):  
Antibody Responses ◽  
Virus Shedding ◽  
Equid Herpesvirus ◽  
Herpesvirus 1

scholarly journals Protection against the New Equine Influenza Virus Florida Clade I Outbreak Strain Provided by a Whole Inactivated Virus Vaccine

Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 784
Author(s):  
Sylvia Reemers ◽  
Sander van Bommel ◽  
Qi Cao ◽  
David Sutton ◽  
Saskia van de Zande
Keyword(s):  
Influenza Virus ◽  
Virus Vaccine ◽  
Clinical Signs ◽  
Field Strain ◽  
Equine Influenza Virus ◽  
Outbreak Strain ◽  
Virus Shedding ◽  
Equine Influenza ◽  
Vaccine Type ◽  
High Level

Equine influenza virus (EIV) is a major cause of respiratory disease in horses. Vaccination is an effective tool for infection control. Although various EIV vaccines are widely available, major outbreaks occurred in Europe in 2018 involving a new EIV H3N8 FC1 strain. In France, it was reported that both unvaccinated and vaccinated horses were affected despite >80% vaccination coverage and most horses being vaccinated with a vaccine expressing FC1 antigen. This study assessed whether vaccine type, next to antigenic difference between vaccine and field strain, plays a role. Horses were vaccinated with an ISCOMatrix-adjuvanted, whole inactivated virus vaccine (Equilis Prequenza) and experimentally infected with the new FC1 outbreak strain. Serology (HI), clinical signs, and virus shedding were evaluated in vaccinated compared to unvaccinated horses. Results showed a significant reduction in clinical signs and a lack of virus shedding in vaccinated horses compared to unvaccinated controls. From these results, it can be concluded that Equilis Prequenza provides a high level of protection to challenge with the new FC1 outbreak strain. This suggests that, apart from antigenic differences between vaccine and field strain, other aspects of the vaccine may also play an important role in determining field efficacy.

REGROWTH AND OVERGROWTH OF THE THYMUS AFTER ATROPHY INDUCED BY THE ORAL ADMINISTRATION OF ADRENOCORTICOSTEROIDS TO HUMAN INFANTS

PEDIATRICS ◽  
1960 ◽  
Vol 26 (5) ◽  
pp. 762-770
Author(s):  
John Caffey ◽  
Robert Silbey
Keyword(s):  
Oral Administration ◽  
Cardiac Catheterization ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Human Infants ◽  
Cardiac Image ◽  
Rapid Regrowth

The oral administration of adrenocorti-costeroids provokes rapid atrophy of the thymus which is followed consistently, after stoppage of the steroid, by rapid regrowth of the thymus and, in some cases, over-growth. Steroid-induced shrinkage of the thymus makes possible visualization of the true cardiac image which is often masked by the overlapping lobes of a large thymus. Such shrinkage may prevent the spurious diagnosis of cardiomegaly, and the use of more elaborate and hazardous methods such as opaque angiocardiography and cardiac catheterization. Steroid shrinkage of the thymus is indicated only in patients who have cardiac signs and symptoms combined with enlarged deformed mediastinums in which the true cardiac image cannot be seen radiographically. Steroid shrinkage is not indicated in patients who have cardiac signs and symptoms combined with small mediastinums, or in patients who have large mediastinums without cardiac signs and symptoms. Steroid shrinkage should not be tried when there are other factors which suggest greater than the probable benefits to be derived from their use. Massive rapid regrowth of the thymus following steroid-inducing atrophy was not associated with clinical signs or symptoms in any of our cases.

scholarly journals A Brazilian glycoprotein E-negative bovine herpesvirus type 1.2a (BHV-1.2a) mutant is attenuated for cattle and induces protection against wild-type virus challenge

2002 ◽  
Vol 22 (4) ◽  
pp. 135-140 ◽  
Author(s):  
Ana Cláudia Franco ◽  
Fernando Rosado Spilki ◽  
Paulo Augusto Esteves ◽  
Marcelo de Lima ◽  
Rudi Weiblen ◽  
...  
Keyword(s):  
Clinical Signs ◽  
Bovine Herpesvirus ◽  
Vaccine Virus ◽  
Parental Virus ◽  
Wild Type Virus ◽  
Wild Type ◽  
Glycoprotein E ◽  
Virus Shedding ◽  
Virus Challenge ◽  
Herpesvirus Type

The authors previously reported the construction of a glycoprotein E-deleted (gE-) mutant of bovine herpesvirus type 1.2a (BHV-1.2a). This mutant, 265gE-, was designed as a vaccinal strain for differential vaccines, allowing the distinction between vaccinated and naturally infected cattle. In order to determine the safety and efficacy of this candidate vaccine virus, a group of calves was inoculated with 265gE-. The virus was detected in secretions of inoculated calves to lower titres and for a shorter period than the parental virus inoculated in control calves. Twenty one days after inoculation, the calves were challenged with the wild type parental virus. Only mild signs of infection were detected on vaccinated calves, whereas non-vaccinated controls displayed intense rhinotracheitis and shed virus for longer and to higher titres than vaccinated calves. Six months after vaccination, both vaccinated and control groups were subjected to reactivation of potentially latent virus. The mutant 265gE- could not be reactivated from vaccinated calves. The clinical signs observed, following the reactivation of the parental virus, were again much milder on vaccinated than on non-vaccinated calves. Moreover, parental virus shedding was considerably reduced on vaccinated calves at reactivation. In view of its attenuation, immunogenicity and protective effect upon challenge and reactivation with a virulent BHV-1, the mutant 265gE- was shown to be suitable for use as a BHV-1 differential vaccine virus.

scholarly journals Effect of tunicamycin and monensin on fusion and hemadsorptive activities of equid herpesvirus 1.

1991 ◽  
Vol 53 (1) ◽  
pp. 133-135
Author(s):  
Nobuo KOIZUMI ◽  
Eiichi HONDA ◽  
Tetsuo KUMAGAI ◽  
Katsunori OKAZAKI
Keyword(s):  
Equid Herpesvirus ◽  
Herpesvirus 1

scholarly journals Susceptibility of tree shrew to SARS-CoV-2 infection

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Yuan Zhao ◽  
Junbin Wang ◽  
Dexuan Kuang ◽  
Jingwen Xu ◽  
Mengli Yang ◽  
...  
Keyword(s):  
Asymptomatic Carrier ◽  
Tree Shrew ◽  
Age Groups ◽  
Clinical Signs ◽  
Economic Losses ◽  
Global Public Health ◽  
Young Tree ◽  
Virus Shedding ◽  
Tree Shrews ◽  
Scientific Questions

Abstract Since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became a pandemic event in the world, it has not only caused huge economic losses, but also a serious threat to global public health. Many scientific questions about SARS-CoV-2 and Coronavirus disease (COVID-19) were raised and urgently need to be answered, including the susceptibility of animals to SARS-CoV-2 infection. Here we tested whether tree shrew, an emerging experimental animal domesticated from wild animal, is susceptible to SARS-CoV-2 infection. No clinical signs were observed in SARS-CoV-2 inoculated tree shrews during this experiment except the increasing body temperature particularly in female animals. Low levels of virus shedding and replication in tissues occurred in all three age groups. Notably, young tree shrews (6 months to 12 months) showed virus shedding at the earlier stage of infection than adult (2 years to 4 years) and old (5 years to 7 years) animals that had longer duration of virus shedding comparatively. Histopathological examine revealed that pulmonary abnormalities were the main changes but mild although slight lesions were also observed in other tissues. In summary, tree shrew is less susceptible to SARS-CoV-2 infection compared with the reported animal models and may not be a suitable animal for COVID-19 related researches. However, tree shrew may be a potential intermediate host of SARS-CoV-2 as an asymptomatic carrier.

scholarly journals A Comprehensive Toxicological Assessment of Fulvic Acid

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Chongshan Dai ◽  
Xilong Xiao ◽  
Yonglei Yuan ◽  
Gaurav Sharma ◽  
Shusheng Tang
Keyword(s):  
Oral Administration ◽  
Fulvic Acid ◽  
Clinical Chemistry ◽  
Clinical Signs ◽  
Micronucleus Assay ◽  
The Body ◽  
Feed Consumption ◽  
Control Group ◽  
Toxicological Studies

Fulvic acid (FA), a humic substance, has several nutraceutical properties, including anti-inflammation, antimicrobial, and immune regulation abilities. However, systematic safety assessment remains insufficient. In the present study, a battery of toxicological studies was conducted per internationally accepted standards to investigate the genotoxicity and repeated-dose oral toxicity of FA. Sprague-Dawley (SD) rats or ICR mice were used. Compared to the control group, there were no significant changes (all p > 0.05 ) in all FA treatment groups in the bacterial reverse mutation test, in vitro mammalian chromosome aberration test, in vivo sperm shape abnormality assay, and in vivo mouse micronucleus assay. The acute toxicity test showed that no mortality or toxic effect was observed following oral administration of the maximum dose of 5,000 mg/kg BW/day to mice or rats. A 60-day subchronic study was conducted at 0 (control), 200, 1,000, and 5,000 mg/kg/day. Compared to the control group, there were no significant changes (all p > 0.05 ) in the body weights, feed consumption, clinical signs, hematology, clinical chemistry, organ weights, or histopathology examinations. In conclusion, the no-observed-adverse-effect-level (NOAEL) of FA supplementation from the 60-day study was determined to be 5,000 mg/kg body weight/day, the highest dose tested. Our findings suggest that the oral administration of FA may have higher safety.

Sign in / Sign up

Export Citation Format

Share Document